Evolving roles of CD38 metabolism in solid tumour microenvironment

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• CD38 is well-understood in multiple myeloma and hematological cancers.
• Its role in non-hematopoietic solid tumors is emerging and debated.
• Therapeutic antibodies targeting CD38 show promise in hematological malignancies.

Purpose of the Study:

• To investigate the bio-function of CD38 enzymatic substrates and metabolites in solid tumors.
• To explore the therapeutic potential of targeting the CD38-NAD+ or CD38-cADPR/ADPR signaling pathways in non-hematopoietic malignancies.
• To review current research and clinical trials for CD38-targeted therapies in solid tumors.

Main Methods:

• Literature review of existing research on CD38 in solid tumors.
• Analysis of biochemical pathways involving CD38 substrates and metabolites.
• Examination of ongoing clinical trials for CD38-targeted therapies.

Main Results:

• Limited but growing evidence suggests CD38's involvement in solid tumor immunology and immune evasion.
• The CD38-NAD+ and CD38-cADPR/ADPR axes are identified as potential therapeutic targets.
• Ongoing research and clinical trials are exploring novel therapeutic strategies.

Conclusions:

• CD38's role in solid tumors warrants further investigation.
• Targeting the CD38 signaling axis presents a promising avenue for novel cancer immunotherapies.
• Continued research is crucial for developing effective CD38-based treatments for solid malignancies.